Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
9.28
-1.07 (-10.34%)
At close: Feb 21, 2025, 4:00 PM
9.27
-0.01 (-0.11%)
After-hours: Feb 21, 2025, 7:59 PM EST
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 500 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
500
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$130,368
Profits / Employee
-$755,502
Market Cap
3.66B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 500 | 0 | - |
Dec 31, 2022 | 500 | 100 | 25.00% |
Dec 31, 2021 | 400 | 69 | 20.85% |
Dec 31, 2020 | 331 | 131 | 65.50% |
Dec 31, 2019 | 200 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RXRX News
- 4 days ago - Altitude Lab Startups Raise $154M in Capital - GlobeNewsWire
- 8 days ago - Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off - Seeking Alpha
- 16 days ago - Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference - GlobeNewsWire
- 6 weeks ago - Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More - GlobeNewsWire
- 6 weeks ago - Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 2 months ago - Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
- 2 months ago - Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability - GlobeNewsWire